Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Clinical trial NCT04052555 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04052555
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Bilateral Breast Carcinoma HER2-Negative Breast Carcinoma Localized Breast Carcinoma Recurrent Breast Carcinoma Triple-Negative Breast Carcinoma

Start date: 2020-09-24
Primary completion: 2027-02-24
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.